Medical expert of the article
New publications
Toxic fibrosing alveolitis
Last reviewed: 18.10.2021
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
The development of toxic fibrosing alveolitis (ICD-10 code: J70.1-J70.8) is due to the toxic effects of chemicals on the respiratory department of the lungs, as well as the damaging effect of immune complexes. In children, toxic fibrosing alveolitis is more often associated with the intake of various drugs (sulfanilamides, methotrexate, mercaptopurine, azathioprine, cicophosphamide (cyclophosphamide), nitrofurantoin (furadonin), furazolidone, hexamethonium benzenesulfonate (benzohexonium), propranolol (anaprilin), hydralazine (apressin), chlorpropamide, benzylpenicillin, penicillamine). In adolescents in the anamnesis - contact in the workplace (gases, metal vapors, herbicides) or substance abuse.
Toxic fibrosing alveolitis has a similar clinical picture and laboratory-functional indices with exogenous allergic alveolitis in the acute and chronic phase of the disease (with the development of pneumofibrosis).
Treatment consists in the urgent cancellation of the drug, which can lead to complete recovery. The appointment of glucocorticoids accelerates the reverse development of pulmonary disorders. With the development of fibrotic changes, treatment effectiveness and prognosis are significantly reduced.